Industry Reports
WuXi AppTec Acquires Biology Focused R&D Service Leader HD Biosciences
WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform announced that it has acquired HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO). After completion...
Industry Reports
OncoGenex Pharmaceuticals and Achieve Life Science Announce Definitive Merger Agreement
OncoGenex Pharmaceuticals, Inc , a publicly held oncology biopharmaceutical company, and Achieve Life Science, Inc , a privately held specialty pharmaceutical company, announced that they have entered into a definitive merger agreement under which OncoGenex will acquire Achieve in...
Industry Reports
Factor One Source Pharmacy to Acquire F.A.S.T. Access Rx
Factor One Source Pharmacy and Fast Access Specialty Therapeutics announced today that they have entered into a definitive agreement under which FOSRx will acquire F.A.S.T. for a combination of cash and stock. Together the two companies...
Industry Reports
Moberg pharma completes acquisition of dermoplast of prestige brands
Moberg Pharma AB has now completed the acquisition of DermoPlast® Prestige Brands, Inc. in accordance with the terms announced on December 6. The purchase price was 47.6 million plus inventory value. DermoPlast® is a topical spray...
Industry Reports
Global Drug Market Will Reach Nearly $1.5 Trillion in 2021
Total spending on medicines is forecast to reach $1.5 trillion by 2021, up 33 percent from 2016 levels, even as annual growth moderates from the record pace set in 2014 and 2015, according to new research released by the...
Industry Reports
Novartis announces phase II SUSTAIN study of SEG101 significantly reduces frequency of sickle cell pain crises
Results from the Phase II SUSTAIN study show that SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the median annual rate of sickle cell-related pain crises (SCPC) by 45.3% compared to placebo (1.63 vs 2.98, p=0.010) in patients with...
Industry Reports
Aegerion Pharmaceuticals INC and QLT INC Complete Merger Transaction ; QLT to Change Name to Novelion Therapeutics Inc
Aegerion Pharmaceuticals Inc and QLT Inc announced the completion of their merger transaction, as a result of which Aegerion is now an indirect wholly-owned subsidiary of QLT. In conjunction with the closing of the merger, QLT changed its name...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
